Butylscopolamine | Market Size, Share & Growth Report 2025-2034
The Butylscopolamine Market Report is Segmented by Product Type (Tablet, Injection, Syrup, Gel, and Patch), Application (Gastrointestinal Disorders, Menstrual Disorders, Urinary Disorders, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Ingredient Type (Butylscopolamine Hydrobromide and Butylscopolamine Methylbromide).
Butylscopolamine Market
Market Analysis
How the market stands today, and what is shaping it
The global butylscopolamine market was estimated at approximately USD 305.0 million in 2025 and is projected to reach around USD 398.0 million by 2034, representing a CAGR of approximately 3.00% during 2025-2034, based on Core Market Research estimates. Butylscopolamine, or hyoscine N-butylbromide, is a smooth-muscle antispasmodic sold mainly as Buscopan and Buscapina tablets, paracetamol combinations and 20 mg/mL injections for hospitals, imaging and palliative care. Growth rests on self-treatment of abdominal cramps, on combination products, on WHO listing of the injection and on rising hospital use in China. Expansion is constrained by the lack of FDA approval for human use, by generic competition for an off-patent molecule and by imaging performance below glucagon. Supply runs through Opella's brands, Boehringer Ingelheim's Australian Duboisia raw material and API makers such as Alkaloids of Australia, so competition turns on brand trust and tender pricing. Asia Pacific concentrates supply and growth, and Opella's April 2025 separation from Sanofi refocuses the leading brands.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Self-treatment of abdominal cramps sustains consumer demand. Opella lists Buscopan among its principal brands in Western Europe, where it is sold through pharmacies for abdominal pain, so recurring cramp episodes can lead to repeat purchases.
- Fixed-dose combinations add value per pack. Buscopan Plus pairs 10 mg hyoscine N-butylbromide with 500 mg paracetamol, and Buscapina Compositum products combine the two in Latin America, addressing pain and spasm together at a higher price than plain tablets.
- WHO listing supports hospital procurement. The 2013 addition of the 20 mg/mL injection to the WHO Model List of Essential Medicines for palliative care gives health systems a basis for including butylscopolamine in national formularies and tenders.
- Brand ownership is being refocused on consumer health. Opella became a standalone company in April 2025, with CD&R holding 50.0 percent, and Buscopan and Buscapina are among its digestive brands, which may sharpen investment in their marketing.
- Demand is growing fastest in China, where Global Industry Analysts expects the hyoscine market to expand at 5.4 percent a year to 2030, against 1.6 percent in Germany and 1.2 percent in Japan, as hospitals adopt branded and generic injections.
Market Challenges
- Hyoscine butylbromide has no FDA approval for human use, excluding the United States from the market.
- In a 2009 Swiss MRI study, butylscopolamine failed to stop bowel motion in half of cases, against none for glucagon.
- Patents have expired in most jurisdictions, the WHO notes, exposing the molecule to low-priced generic competition.
- Scopolamine starting material depends on Duboisia plantations in eastern Australia, concentrating raw material supply in one region.
Opportunities
- New fixed-dose combinations with analgesics could extend Buscopan and Buscapina into wider pain indications.
- Hospital demand in China, growing at a projected 5.4 percent a year, may reward suppliers of injectable butylscopolamine.
- Palliative care programmes using the WHO-listed injection could expand procurement in lower-income health systems.
- Use in CT colonography and abdominal MRI may support injection demand where glucagon is costlier or less available.
Trends and Insights
Key market trends shaping the industry landscape
Consumer health carve-outs
Medium impactMid-termLarge drugmakers are separating consumer brands into standalone companies.
Insight: Buscopan moved from Boehringer Ingelheim to Sanofi in 2017 and into the standalone Opella in 2025, which may bring more focused brand investment in over-the-counter antispasmodics.
Antispasmodic-analgesic combinations
Medium impactShort-termBrands are adding paracetamol combinations to plain butylscopolamine tablets.
Insight: Combinations such as Buscopan Plus and Buscapina Compositum treat pain and spasm in one tablet, which lifts value per pack in a mature, off-patent market.
Growth shifting to China
Medium impactLong-termHyoscine demand is growing faster in China than in Europe and Japan.
Insight: Global Industry Analysts' projections of 5.4 percent a year for China against 1.6 percent for Germany suggest future volume growth may come mainly from Asian hospital use.
Hydrobromide outpacing butyl bromide
Low impactMid-termScopolamine hydrobromide is growing faster than the butyl bromide type.
Insight: Global Industry Analysts expects 4.3 percent annual growth for hydrobromide against 2.3 percent for butyl bromide, suggesting motion-sickness and other uses are gaining on antispasmodic demand.
Segment Analysis
Market segmentation by product type, application, distribution channel, ingredient type
Tablet is the main consumer form, sold as Buscopan 10 mg tablets for abdominal cramps and in fixed-dose combinations with paracetamol, such as Buscopan Plus with 500 mg paracetamol and Colombia's Buscapina Compositum NF with 325 mg. Injection is the hospital form, with 20 mg/mL ampoules listed on the WHO Essential Medicines List for palliative care and used as an antispasmodic in abdominal imaging. Patch products contain scopolamine hydrobromide for motion sickness rather than butylscopolamine, so they sit outside the core molecule. Syrup and Gel forms are niche, and no separate value was identified for either.
Geography Analysis
Regional market analysis
North America
North America is a small market for butylscopolamine, because hyoscine butylbromide has no FDA approval for human use in the United States, where methscopolamine, hyoscyamine and dicyclomine are used instead. Global Industry Analysts' USD 115.6 million U.S. hyoscine figure for 2024 therefore reflects other hyoscine forms such as scopolamine hydrobromide. Global Industry Analysts expects Canada's hyoscine market to grow 2.2 percent a year. The regional constraint is regulatory, since the absence of a U.S. approval excludes the largest pharmaceutical market from butylscopolamine sales.
Europe
Europe is a core market for Buscopan, which Opella lists among its principal Western European brands alongside Dulcolax and Allegra. Combination products such as Buscopan Plus with paracetamol are sold through pharmacies, including online pharmacies in Austria. Hospitals use butylscopolamine injections in abdominal imaging, studied at the University of Bern against glucagon. Global Industry Analysts expects Germany's hyoscine market to grow about 1.6 percent a year. The regional constraint is maturity, with an off-patent molecule and established brands limiting growth.
Asia Pacific
Asia Pacific is the largest region on a supply and demand concentration basis rather than on a published butylscopolamine regional market size. Boehringer Ingelheim grows about 990 hectares of Duboisia in eastern Australia, and Alkaloids of Australia makes hyoscine butylbromide API at Kingaroy, close to the plantations. Global Industry Analysts projects China's hyoscine market to grow at 5.4 percent a year to USD 97.8 million by 2030, faster than Japan at 1.2 percent, and China has tested a branded butylscopolamine injection against anisodamine in a Phase III trial. The regional constraint is price competition from domestic generics.
Latin America
Latin America sells butylscopolamine mainly under the Buscapina name, now an Opella brand, including combinations with paracetamol such as Buscapina Compositum N in Argentina and Peru and Buscapina Compositum NF in Colombia. Boehringer Ingelheim studied the combination's use in adults in Lima in 2016. No separate Latin American market size or growth figure was identified in the sources reviewed. The regional constraint is dependence on a single brand family, which leaves pricing exposed to local generic competition.
Middle East & Africa
Middle East & Africa uses butylscopolamine injections and tablets in hospitals and pharmacies, and the WHO's 2013 listing of the 20 mg/mL injection supports its inclusion in national essential medicines lists across the region. Generic injections are also offered by manufacturers in the United Arab Emirates. No regional market size, revenue or growth figure was identified in the sources reviewed. The regional constraint is reliance on low-priced generic procurement, which limits value per unit.
Competitive Landscape
Key players and market positioning analysis
Butylscopolamine is an off-patent molecule supplied by one originator brand family and many generic manufacturers, built on a raw material chain concentrated in Australia. Three independent participants could be verified, ordered by the breadth of their role in the market. Opella owns Buscopan and Buscapina, the originator brands, including paracetamol combinations sold across Europe and Latin America, after Sanofi sold a 50.0 percent controlling stake to CD&R in April 2025. Boehringer Ingelheim, which developed Buscopan and sold its consumer business to Sanofi in 2017, has grown about 990 hectares of Duboisia in eastern Australia, according to CSIRO, to supply scopolamine for semi-synthetic anticholinergics. Alkaloids of Australia makes hyoscine butylbromide API at Kingaroy, near those plantations. Generic injections and tablets are made by manufacturers in Europe, China, the United Arab Emirates and India, and in China a branded injection has been compared with anisodamine in a Phase III trial. Competition therefore turns on brand trust in self-medication, price in hospital tenders and access to scopolamine raw material, and positioning may depend on combinations and growth in Chinese hospital use.
Major Players
Leading companies in the market
Industry Developments
5 recorded developments
Sanofi completed the sale of a 50.0 percent controlling stake in its consumer healthcare business Opella to CD&R on 30 April 2025, keeping 48.2 percent, with Bpifrance holding 1.8 percent. Buscopan and its Latin American counterpart Buscapina became brands of the standalone Opella.
Sanofi took over Boehringer Ingelheim's consumer healthcare business, including Buscopan, in January 2017 in exchange for its Merial animal health business. Boehringer Ingelheim continues to source scopolamine from Duboisia hybrid leaf, which a 2014 company paper describes as the starting material for semi-synthetic anticholinergics.
Boehringer Ingelheim registered an observational study of Buscapina Compositum N, combining 10 mg hyoscine N-butylbromide with 500 mg paracetamol, in adults in metropolitan Lima, Peru, as NCT02910167. The study examined adverse events and drug utilisation for the combination in Latin America.
The WHO added hyoscine butylbromide 20 mg/mL injection to its Model List of Essential Medicines as a core palliative care medicine, to manage respiratory secretions in dying patients. The listing supports its inclusion in national procurement lists, although the WHO committee described the evidence for that use as weak.
A Swiss MRI study in 10 healthy volunteers compared hyoscine N-butylbromide with glucagon for stopping small-bowel peristalsis. Aperistalsis lasted a mean 6.8 minutes after butylscopolamine against 18.3 minutes after glucagon, and butylscopolamine failed to achieve aperistalsis in half of cases, defining its limits as an imaging agent.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Product Type
5.3 By Application
5.4 By Distribution Channel
5.5 By Ingredient Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Opella
9.2 Boehringer Ingelheim International GmbH
9.3 Alkaloids of Australia Pty Ltd
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2034
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Opella, Boehringer Ingelheim International GmbH, Alkaloids of Australia Pty Ltd + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.